Study of patient characteristics, treatment patterns, EGFR testing patterns and outcomes in real-world patients with EGFRm⁺ non-small cell lung cancer

References

• American Cancer Society. Lung and bronchus [Internet]. Farmingham (MA): ACS; 2020 [cited 2021 Feb 10]. Available from: http://cancerstatisticscenter.cancer.org/#/cancer-site/Lung%20and%20bronchus
   Google Scholar
• Walters S, Maringe C, Coleman MP, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. Thorax. 2013;68(6):551–564.
   PubMed Web of Science ®Google Scholar
• American Society for Clinical Oncology. Lung cancer - non-small cell: statistics [Internet]. Alexandria (VA): ASCO; 2020 [cited 2021 Feb 11]. Available from: https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics#:∼:text=NSCLC%20is%20the%20most%20common,be%20diagnosed%20with%20lung%20cancer
   Google Scholar
• Gower A, Wang Y, Giaccone G. Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. J Mol Med. 2014;92(7):697–707.
   PubMed Web of Science ®Google Scholar
• Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892–2911.
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Varella-Garcia M, Cappuzzo F, et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol. 2007;18(4):752–760.
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Bunn PA. Jr. EGFR testing in lung cancer is ready for prime time. Lancet Oncol. 2009;10(5):432–433.
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23(11):2513–2520.
   PubMed Web of Science ®Google Scholar
• Gilotrif (Afatinib) [Internet]. Ingelheim am Rhein (Germany): Boehringer Ingelheim Pharmaceuticals; 2013 [cited 2021 Sep 28]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/201292s014lbl.pdf
   Google Scholar
• Girard N. Optimizing outcomes and treatment sequences in EGFR mutation-positive non-small-cell lung cancer: recent updates. Future Oncol. 2019;15(25):2983–2997.
   PubMed Web of Science ®Google Scholar
• Roeper J, Kurz S, Grohe C, et al. Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC. Future Oncol. 2021;17(4):471–486.
   PubMed Web of Science ®Google Scholar
• Suda K, Onozato R, Yatabe Y, et al. EGFR T790M mutation: a double role in lung cancer cell survival? J Thorac Oncol. 2009;4(1):1–4.
   PubMed Web of Science ®Google Scholar
• Hakozaki T, Yomota M. Acquisition of T790M resistance mutation in a patient with advanced adenocarcinoma harbouring uncommon EGFR mutations: a case report and literature review. Onco Targets Ther. 2019;12:745–748.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–640.
   PubMed Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–125.
   PubMed Web of Science ®Google Scholar
• Niederst MJ, Hu H, Mulvey HE, et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res. 2015;21(17):3924–3933.
   PubMed Web of Science ®Google Scholar
• Hochmair MJ, Morabito A, Hao D, et al. Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. Future Oncol. 2018;14(27):2861–2874.
   PubMed Web of Science ®Google Scholar
• Ma X, Long L, Moon S, et al. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. medRxiv. 2020. 2020.03.16.20037143.
   Google Scholar
• Birnbaum BE, Nussbaum N, Seidl-Rathkopf KN, et al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. ArXiv. 2020. abs/2001.09765.
   Google Scholar
• Guo C, Liang Y. Analyzing restricted mean survival time using SAS/STAT. Cary (NC): SAS Institute Inc.; 2019.
   Google Scholar
• Altman DG, Bland JM. Standard deviations and standard errors. BMJ. 2005;331(7521):903.
   PubMed Web of Science ®Google Scholar
• Green JA. Osimertinib-first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer? J Thorac Dis. 2018;10(33):S3837–S3839.
   PubMed Web of Science ®Google Scholar
• Pennell NA, Arcila ME, Gandara DR, et al. Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices. Am Soc Clin Oncol Educ Book. 2019;39:531–542.
   PubMedGoogle Scholar
• Hirsh V. Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors. Ther Adv Med Oncol. 2018;10:1758834017753338.
   Web of Science ®Google Scholar
• Li Y, Appius A, Pattipaka T, et al. Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA. PLoS One. 2019;14(1):e0209709.
   PubMed Web of Science ®Google Scholar
• Gautam S, Herms L, Bartolome L, et al. Real-world effectiveness of EGFR TKI first-line treatment of advanced EGFR mutation-positive non small cell lung cancer in US. Paper presented at the IASLC 2020 World Conference on Lung Cancer Singapore; 2021 January 28–31; Singapore.
   Google Scholar
• Addeo A, Hochmair M, Janzic U, et al. Real-world treatment patterns, clinical outcomes and EGFR/T790M testing practices in patients with EGFRm advanced NSCLC and 1L EGFR TKI therapy: a retrospective multinational study (REFLECT). Ann Oncol. 2020;31:S840.
   PubMed Web of Science ®Google Scholar
• Mason C, Ellis PG, Lokay K, et al. Patterns of biomarker testing rates and appropriate use of targeted therapy in the first-line, metastatic non-small cell lung cancer treatment setting. J Clin Pathw. 2018;4(1):49–54.
   PubMedGoogle Scholar
• Mamdani H, Ahmed S, Armstrong S, et al. Blood-based tumor biomarkers in lung cancer for detection and treatment. Transl Lung Cancer Res. 2017;6(6):648–660.
   PubMed Web of Science ®Google Scholar
• Mao C, Yuan JQ, Yang ZY, et al. Blood as a substitute for tumor tissue in detecting EGFR mutations for guiding EGFR TKIs treatment of nonsmall cell lung cancer: a systematic review and meta-analysis. Medicine. 2015;94(21):e775.
   PubMed Web of Science ®Google Scholar